Welcome to our dedicated page for Pmv Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on Pmv Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (PMV Pharma; Nasdaq: PMVP) is a precision oncology clinical-stage company focused on small molecule, tumor-agnostic therapies targeting p53. News about PMV Pharma centers on the clinical and regulatory progress of its lead investigational therapy, rezatapopt (PC14586), and the advancement of its p53-focused pipeline.
Readers following PMVP news can expect frequent updates on the PYNNACLE Phase 1/2 clinical trial, which evaluates rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. Company announcements describe interim and updated Phase 2 data, including overall response rates and duration of response across cohorts such as ovarian, lung, breast, endometrial cancers, and other solid tumors with TP53 Y220C and KRAS wild-type status.
PMV Pharma’s news flow also includes financial results and corporate highlights, typically released quarterly and annually. These updates summarize research and development spending, general and administrative expenses, cash, cash equivalents, and marketable securities, and provide commentary on expected cash runway to support ongoing clinical development.
Additional news items cover scientific presentations and collaborations, such as oral and poster presentations at oncology and pharmacology conferences, investigator-initiated studies in AML/MDS, and partnerships related to companion diagnostics. Investors and observers can use this page to track rezatapopt’s development, regulatory interactions, and PMV Pharma’s broader precision oncology strategy. For those monitoring PMVP, regularly reviewing this news feed provides a consolidated view of clinical milestones, data disclosures, and corporate developments.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported Q1 2022 financial results, highlighting $294.8 million in cash and a net loss of $18.4 million. R&D expenses increased to $11.8 million, driven by advancing PC14586, a first-in-class p53 Y220C reactivator. General and administrative costs rose to $6.8 million, reflecting infrastructure growth as a public company. The company emphasized its focus on executing the Phase 1/2 PYNNACLE trial and presenting initial data at the 2022 ASCO meeting on June 7.
PMV Pharmaceuticals (PMVP) has announced that initial data from its ongoing Phase 1 study of PC14586 will be presented at the 2022 ASCO Annual Meeting. This investigational therapy targets patients with advanced solid tumors featuring a p53 Y220C mutation. The oral presentation is scheduled for June 7, 2022, at 9:45 AM CDT, under the title 'First-in-human study of PC14586.' PC14586 aims to restore the normal function of p53 proteins, pivotal in cancer suppression. Detailed insights will be shared regarding its progress in the clinical trial process.
PMV Pharmaceuticals (PMVP) has made significant progress in its Phase 1/2 trial of PC14586, targeting advanced solid tumors with p53 Y220C mutations. As of December 31, 2021, the company reported a cash position of $314.1 million, down from $361.4 million in 2020. The net loss for 2021 was $57.8 million, an increase from $34.4 million in 2020, largely due to higher R&D and G&A expenses. While patient enrollment continues on track, the company anticipates initial results from the trial in mid-2022, aiming to expand its pipeline with additional p53-targeting therapies.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will participate in a panel on lung cancer at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022. The panel discussion is scheduled for March 9, 2022, from 9:10 AM to 10:10 AM EST. The company, focused on developing small molecule therapies targeting p53 mutations, aims to connect with institutional investors during the conference.
PMV Pharma was founded to innovate in oncology, leveraging over 40 years of research into p53 biology.
PMV Pharmaceuticals, a precision oncology company, announced that its CEO, David H. Mack, will participate in a Fireside Chat at the Guggenheim Healthcare Talks 2022 Oncology Day on February 9, 2022, at 10:30 am ET. This event will include one-on-one investor meetings, emphasizing PMV's focus on tumor-agnostic therapies targeting p53 mutants. The company is recognized for its groundbreaking work in p53 biology, established by co-founder Dr. Arnold Levine in 1979. For more details, visit PMV Pharma's website.
PMV Pharmaceuticals (Nasdaq: PMVP) announced the appointment of Kirsten Flowers to its Board of Directors, effective January 6, 2022. This change follows the resignation of Peter Thompson, M.D., who contributed to the company's growth and IPO success. Flowers brings extensive experience in oncology product launches and commercial strategy, previously serving as Chief Commercial Officer at Kura Oncology and leading Array Biopharma's first commercial launch. Her expertise is expected to enhance PMV's strategy as it advances its candidate PC14586 targeting p53 mutations.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a leader in precision oncology, announced that David H. Mack, Ph.D., will participate in a "Fireside Chat" at the Evercore ISI 4th Annual HealthCONx Conference from November 30 to December 2, 2021. The chat is scheduled for December 2, 2021, at 11:20 am ET. PMV Pharma specializes in developing small molecule therapies targeting p53 mutations, which are prevalent in about half of all cancers. This event will also include one-on-one investor meetings.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported its Q3 2021 financial results, highlighting significant developments in its lead candidate, PC14586, targeting p53 Y220C mutations. With a robust cash position of $326.3 million as of September 30, 2021, PMVP anticipates sufficient funds to support operations through 2023. However, the company recorded a net loss of $39.5 million for the first nine months of 2021, up from $24.0 million in the same period last year, driven by increased R&D and G&A expenses.
PMV Pharmaceuticals (Nasdaq: PMVP) has appointed Tim Smith as Senior Vice President, Head of Corporate Development. Smith brings extensive experience from previous leadership roles in biotechnology, including Verseau Therapeutics and IDEAYA Biosciences. His expertise is expected to enhance PMV's efforts in developing tumor-agnostic therapies targeting p53 mutants, crucial for many cancers. The company's lead candidate, PC14586, aims to reactivate the p53 protein in patients with specific mutations.
PMV Pharmaceuticals (Nasdaq: PMVP) announced that its CEO, David H. Mack, Ph.D., will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 PM ET. The company is known for its innovative work in precision oncology, focusing on small molecule therapies targeting p53 mutants, which are implicated in nearly half of all cancers. PMV Pharma aims to revolutionize cancer treatment through its unique insights into p53 biology, established by co-founder Dr. Arnold Levine in 1979.